Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HC Surgical SpecialistsSGX:1B1 +1.45%63 Return-on-Tangible-Equity is 33.47% as of May. 2026, which is 18% below its 10-year median of 40.93. GuruFocus rates SGX:1B1 with a GF Score™ of 63/100 and a GF Value™ of S$0.30 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 188 Medical Diagnostics & Research companies, HC Surgical Specialists ranks better than 80.85% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. HC Surgical Specialists's annualized net income for the quarter that ended in May. 2026 was S$6.03 Mil. HC Surgical Specialists's average shareholder tangible equity for the quarter that ended in May. 2026 was S$18.00 Mil. Therefore, HC Surgical Specialists's annualized Return-on-Tangible-Equity for the quarter that ended in May. 2026 was 33.47%.
The historical rank and industry rank for HC Surgical Specialists's Return-on-Tangible-Equity or its related term are showing as below:
SGX:1B1'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 20.83 Med: 40.93 Max: 106.31
Current: 39.12
During the past 13 years, HC Surgical Specialists's highest Return-on-Tangible-Equity was 106.31%. The lowest was 20.83%. And the median was 40.93%.
SGX:1B1's Return-on-Tangible-Equity is ranked better than 80.85% of 188
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.455
vs SGX:1B1: 39.12
HC Surgical Specialists (SGX:1B1) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
HC Surgical Specialists Return-on-Tangible-Equity Related Terms
HC Surgical Specialists Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for HC Surgical Specialists's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HC Surgical Specialists Return-on-Tangible-Equity Chart
SGX:1B1 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, HC Surgical Specialists's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HC Surgical Specialists Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, HC Surgical Specialists's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where HC Surgical Specialists's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (May. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 33.47% mean?
HC Surgical Specialists (SGX:1B1) has a Return-on-Tangible-Equity of 33.47% as of May. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on HC Surgical Specialists and its competitors. This is 18% below median its historical median of 40.93. Over the past decade, HC Surgical Specialists' Return-on-Tangible-Equity has ranged from 20.83 to 106.31. According to the industry distribution chart, HC Surgical Specialists ranks #36 out of 188 companies in the Medical Diagnostics & Research industry, placing it in the top 19.1%.
Is HC Surgical Specialists' Return-on-Tangible-Equity too high?
HC Surgical Specialists' current Return-on-Tangible-Equity of 33.47% is 18% below median its 10-year median of 40.93. Over the past 10 years, this metric has ranged from a low of 20.83 to a high of 106.31. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 0.46. HC Surgical Specialists' value of 33.47% is 7256% above this industry median. Based on the distribution chart, HC Surgical Specialists ranks #36 out of 188 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, HC Surgical Specialists has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HC Surgical Specialists' Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, HC Surgical Specialists ranks #36 out of 188 companies for Return-on-Tangible-Equity. This places HC Surgical Specialists in the top 19% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 0.46. HC Surgical Specialists' value of 33.47% is 7256% above this benchmark. Historically, HC Surgical Specialists' own Return-on-Tangible-Equity has ranged from 20.83 to 106.31 over the past decade. While the company's 10-year median is 40.93 vs. the industry median of 0.46, HC Surgical Specialists has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.46, based on 188 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HC Surgical Specialists's current Return-on-Tangible-Equity of 33.47% is 7256% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on HC Surgical Specialists and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HC Surgical Specialists's current Return-on-Tangible-Equity is 33.47%, which is 18% below median its own 10-year median of 40.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HC Surgical Specialists stock overvalued right now?
Based on GuruFocus' analysis, HC Surgical Specialists (SGX:1B1) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.30, compared to a current price of S$0.35 — trading 16.7% above its estimated fair value. The current Return-on-Tangible-Equity is 33.47%, which is 18% below median its 10-year median of 40.93 and 7256% above the Medical Diagnostics & Research industry median of 0.46. HC Surgical Specialists' overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For HC Surgical Specialists (SGX:1B1), the current Return-on-Tangible-Equity is 33.47% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HC Surgical Specialists (SGX:1B1) Overvalued in 2026?
Based on GuruFocus' analysis, HC Surgical Specialists stock appears to be overvalued.
The current stock price of S$0.35 is trading 16.7% above its estimated GF Value™ of S$0.30.
GuruFocus considers HC Surgical Specialists to be Modestly Overvalued.
Key valuation signals for SGX:1B1:
Return-on-Tangible-Equity: 33.47% (18% below median its 10-year median of 40.93)
GF Value™: S$0.30 vs. price of S$0.35 (16.7% above fair value)
Industry Position: 7256% above the Medical Diagnostics & Research median (#36 of 188)
No single metric tells the full story. See the SGX:1B1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HC Surgical Specialists Ltd is a medical services group. The company is engaged in providing endoscopic procedures, including gastroscopies and colonoscopies, and general surgery services. The operating segment of the company is the healthcare segment. Geographically, it operates only in Singapore. The company has its facilities center and clinics at various places in Singapore.
63GF Score
Get the complete analysis for SGX:1B1
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:1B1 has been successfully added to your 
